Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THEROS: Osimertinib in T790M-Negative/Unknown EGFR-Mutated NSCLC
NCT03810066Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Universitätsmedizin Essen. Primary endpoint: Rate of metabolic responses at 28 days. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03810066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03810066.